Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL216981 (Mk-7123, Navarixin, PS-291822, PS291822, SCH-527123, SCH527123) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
CCR7/C-C chemokine receptor type 7 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4594] [GtoPdb: 64] [UniProtKB: P32248] | ||||||||
ChEMBL | Antagonist activity at CCR7 in human CD4 cells by fluorescence based calcium mobilization assay | F | 5.33 | pIC50 | 4680 | nM | IC50 | Eur J Med Chem (2023) 251: 115240-115240 [PMID:36924670] |
CXCR2 in Human [GtoPdb: 69] [UniProtKB: P25025] | ||||||||
GtoPdb | - | - | 10.31 | pIC50 | 0.05 | nM | IC50 |
Pharmacol Rev (2014) 66: 1-79 [PMID:24218476]; J Med Chem (2006) 49: 7603-6 [PMID:17181143] |
CXCR2/C-X-C chemokine receptor type 2 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4105830] [GtoPdb: 69] [UniProtKB: P35343] | ||||||||
ChEMBL | Antagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysis | B | 8.09 | pIC50 | 8.1 | nM | IC50 | J Med Chem (2018) 61: 2518-2532 [PMID:29406702] |
CXCR1/Interleukin-8 receptor A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4029] [GtoPdb: 68] [UniProtKB: P25024] | ||||||||
ChEMBL | Binding affinity to NanoLuc fused Snap CXCR1 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay | B | 7.66 | pKi | 21.88 | nM | Ki | J Med Chem (2023) 66: 12911-12930 [PMID:37523859] |
ChEMBL | Binding affinity to CXCR1 | B | 7.7 | pKi | 20 | nM | Ki | Bioorg Med Chem Lett (2009) 19: 1431-1433 [PMID:19196511] |
ChEMBL | Displacement of [125I]IL8 from human CXCR1 expressed in CHO cells by SPA | B | 7.74 | pKi | 18 | nM | Ki | Bioorg Med Chem Lett (2007) 17: 3778-3783 [PMID:17459706] |
ChEMBL | Antagonist activity at CXCR1 (unknown origin) stably expressed in HEK293 cells assessed as reduction in IL-8-induced intracellular calcium change incubated for 15 mins followed by IL-8-stimulation and measured after 15 mins by cAMP-d2/Eu-Anti-cAM based fluorescence assay | F | 6.7 | pIC50 | 198.3 | nM | IC50 | Eur J Med Chem (2020) 187: 111914-111914 [PMID:31806538] |
ChEMBL | Antagonist activity at CXCR1 (unknown origin) expressed in HEK293 cells assessed as suppression of IL-8-induced inhibition of forskolin-induced cAMP formation preincubated for 15 mins followed by forskolin and IL-8 stimulation and measured after 15 mins by cAMP-d2 and Eu-Anti-cAMP based fluorescence assay | F | 6.7 | pIC50 | 198.3 | nM | IC50 | Eur J Med Chem (2020) 205: 112537-112537 [PMID:32768738] |
ChEMBL | Antagonist activity in CXCR1 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay | F | 6.8 | pIC50 | 160 | nM | IC50 | ACS Med Chem Lett (2021) 12: 836-845 [PMID:34055234] |
ChEMBL | Displacement of [125I]hCXCL8 from human CXCR1 receptor expressed in BaF3 cells | B | 7.44 | pIC50 | 36 | nM | IC50 | J Med Chem (2006) 49: 7603-7606 [PMID:17181143] |
ChEMBL | Antagonist activity at CXCR1 (unknown origin) | B | 7.44 | pIC50 | 36 | nM | IC50 | RSC Med Chem (2021) 12: 1046-1064 [PMID:34355177] |
ChEMBL | Binding affinity to CXCR1 | B | 8.41 | pIC50 | 3.9 | nM | IC50 | J Med Chem (2012) 55: 9363-9392 [PMID:22931505] |
GtoPdb | - | - | 8.41 | pIC50 | 3.9 | nM | IC50 |
Pharmacol Rev (2014) 66: 1-79 [PMID:24218476]; J Med Chem (2006) 49: 7603-6 [PMID:17181143] |
CXCR2/Interleukin-8 receptor B in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2434] [GtoPdb: 69] [UniProtKB: P25025] | ||||||||
ChEMBL | Binding affinity to CXCL2 (unknown origin) | B | 10.3 | pKd | 0.05 | nM | Kd | J Med Chem (2023) 66: 12911-12930 [PMID:37523859] |
ChEMBL | Displacement of [3H]Sch527123 from human CXCR2 assessed as dissociation constant measured every 30 secs for 48 hrs by radioligand binding assay | B | 10.31 | pKd | 0.05 | nM | Kd | J Med Chem (2023) 66: 12911-12930 [PMID:37523859] |
ChEMBL | Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA | B | 8.3 | pKi | 5 | nM | Ki | Bioorg Med Chem Lett (2007) 17: 3778-3783 [PMID:17459706] |
ChEMBL | Displacement of human [125I]IL-8 from human CXCR2 | B | 8.3 | pKi | 5 | nM | Ki | Bioorg Med Chem Lett (2009) 19: 4446-4449 [PMID:19525110] |
ChEMBL | Binding affinity to CXCR2 | B | 8.4 | pKi | 4 | nM | Ki | Bioorg Med Chem Lett (2009) 19: 1431-1433 [PMID:19196511] |
ChEMBL | Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay | B | 9.19 | pKi | 0.65 | nM | Ki | J Med Chem (2023) 66: 12911-12930 [PMID:37523859] |
ChEMBL | Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis | B | 6.17 | pIC50 | 680 | nM | IC50 | J Med Chem (2018) 61: 2518-2532 [PMID:29406702] |
ChEMBL | Antagonist activity at CXCR2 in human whole blood by CD11b assay | B | 6.35 | pIC50 | 450 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5493-5496 [PMID:25455491] |
ChEMBL | Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay | F | 8 | pIC50 | 10 | nM | IC50 | ACS Med Chem Lett (2021) 12: 836-845 [PMID:34055234] |
ChEMBL | Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay | F | 8.3 | pIC50 | 5 | nM | IC50 | Eur J Med Chem (2023) 251: 115240-115240 [PMID:36924670] |
ChEMBL | Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay | F | 8.54 | pIC50 | 2.88 | nM | IC50 | J Med Chem (2023) 66: 12911-12930 [PMID:37523859] |
ChEMBL | Antagonist activity at CXCR2 (unknown origin) | B | 8.59 | pIC50 | 2.6 | nM | IC50 | RSC Med Chem (2021) 12: 1046-1064 [PMID:34355177] |
ChEMBL | Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells | B | 8.59 | pIC50 | 2.6 | nM | IC50 | J Med Chem (2006) 49: 7603-7606 [PMID:17181143] |
ChEMBL | Inhibition of CXCL1-induced human neutrophil chemotaxis | F | 9 | pIC50 | <1 | nM | IC50 | J Med Chem (2006) 49: 7603-7606 [PMID:17181143] |
ChEMBL | Binding affinity to CXCR2 | B | 10.31 | pIC50 | 0.05 | nM | IC50 | J Med Chem (2012) 55: 9363-9392 [PMID:22931505] |
GtoPdb | - | - | 10.31 | pIC50 | 0.05 | nM | IC50 |
Pharmacol Rev (2014) 66: 1-79 [PMID:24218476]; J Med Chem (2006) 49: 7603-6 [PMID:17181143] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]